Vaccination against cutaneous leishmaniasis: Current status

American Journal of Clinical Dermatology

Volumn 3, Issue 8, 2002, Pages 557-570

  Melby, P C ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; BCG VACCINE; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE 5; DNA; DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN GP 63; GLYCOPROTEIN GP 64; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; LEISHMANIA EUKARYOTIC INITIATION FACTOR; LEISHMANIA HOMOLOG OF RECEPTOR FOR ACTIVATED PROTEIN KINASE C; LEISHMANIA MAJOR STRESS IDUCIBLE 1 PROTEIN; LEISHMANIA PIFANOI AMASTIGOTE STAGE SPECIFIC MEMBRANE PROTEIN; LEISHMANIA VACCINE; LIPOPHOSPHOGLYCAN; LIVE VACCINE; OLIGONUCLEOTIDE; PARASITE ANTIGEN; PROMASTIGOTE SURFACE ANTIGEN 2; RECOMBINANT ANTIGEN; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 2; RECOMBINANT PROTEIN; THIOL SPECIFIC ANTIOXIDANT PROTEIN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DISEASE TRANSMISSION; DNA MODIFICATION; DRUG EFFICACY; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNITY; LEISHMANIA; LEISHMANIA MAJOR; MACROPHAGE ACTIVATION; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; PSYCHODIDAE; REVIEW; SALIVA; SKIN LEISHMANIASIS; SKIN ULCER; VACCINATION;

EID: 0036035705     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200203080-00006     Document Type: Review

References (152)

1. Anonymous. World Health Organization. Leishmaniasis Control Home Page [online]. Available from URL: http://www.who.int/emc/diseases/leish/index.html [Accessed 2002 Jan 8]
2. Weigle KA, Santrich C, Martinez F, et al. Epidemiology of cutaneous leishmaniasis in Colombia: A longitudinal study of the natural history, prevalence, and incidence of infection and clinical manifestations. J Infect Dis 1993; 168: 699-708
3. Weigle KA, Valderrama L, Arias AL, et al. Leishmanin skin test standardization and evaluation of safety, dose, storage, longevity of reaction and sensitization. Am J Trop Med Hyg 1991; 44: 260-71
4. Andrade-Narvaez FJ, Simmonds-Diaz E, Rico-Aguilar S, et al. Incidence of localized cutaneous leishmaniasis (chiclero's ulcer) in Mexico. Trans R Soc Trop Med Hyg 1990; 84: 219-20
5. Davies CR, Llanos-Cuentas EA, Pyke SD, et al. Cutaneous leishmaniasis in the Peruvian Andes: An epidemioiogical study of infection and immunity. Epidemiol Infect 1995; 114: 297-318
6. Guirges SY. Natural and experimental re-infection of man with Oriental sore. Ann Trop Med Parasitol 1971; 65: 197-205
7. Saravia NG, Weigle K, Segura I, et al. Recurrent lesions in human Leishmania braziliensis infection: Reactivation or reinfection? Lancet 1990; 336: 398-402
8. Sokolova AN. Preventive vaccination with the living parasites of cutaneous leishmaniasis. Trans Turkmen Cutan-Venereol Inst Ashkhabad 1940, 11-44
9. Marzinowsky EI, Schurenkowa A. Oriental sore and immunity against it. Trans R Soc Trop Med Hyg 1924; 18: 67-9
10. Moshkovsky CD. The 'principle of re-inoculation' in oriental sore in relation to prophylactic vaccination. Med Parasit Parasitic Dis 1942; 11: 66-75
11. Berberian DA. Vaccination and immunity against oriental sore. Trans R Soc Trop Med Hyg 1939; 223: 1417-9
12. Berberian DA. Cutaneous leishmaniasis (oriental sore): I, time required for development of immunity after vaccination. Arch Dermatol Syph 1944; 49: 433-5
13. Sagher F, Verbi S, Zuckerman A. Immunity to reinfection following recovery from cutaneous leishmaniasis (oriental sore). J Invest Dermatol 1955; 24: 417-21
14. Senekji HA, Beattie CP. Artificial infection and immunization of man with cultures of Leishmania tropica. Trans R Soc Trop Med Hyg 1941; 34: 415-9
15. Dostrovsky A, Sagher F, Zuckerman A. Isophasic reaction following experimental superinfection of Leishmania tropica. Arch Dermatol Syph 1952; 66: 665-75
16. Heinzel FP, Sadick MD, Holaday BJ, et al. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis: Evidence for expansion of distinct helper T cell subsets. J Exp Med 1989; 169: 59-72
17. Heinzel FP, Sadick MD, Mutha SS, et al. Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl Acad Sci U S A 1991; 88: 7011-5
18. Sadick MD, Locksley RM, Tubbs C, et al. Murine cutaneous leishmaniasis: Resistance correlates with the capacity to generate interferon-gamma in response to Leishmania antigens in vitro. J Immunol 1986; 136: 655-61.
19. Scott P, Natovitz P, Coffman RL, et al. Immunoregulation of cutaneous leishmaniasis: T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med 1988; 168: 1675-84
20. Heinzel FP, Rerko RM, Hujer AM. Underproduction of interleukin-12 in susceptible mice during progressive leishmaniasis is due to decreased CD40 activity. Cell Immunol 1998; 184: 129-42
21. Heinzel FP, Rerko RM, Ahmed F, et al. Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice. J Immunol 1995; 155: 730-9
22. Carvalho EM, Johnson WD, Barreto E, et al. Cell mediated immunity in American cutaneous and mucosal leishmaniasis. J Immunol 1985; 135: 4144-8
23. Cooper AM, Melby PC, Karp CL, et al. T-cell responses to infected autologous monocytes in patients with cutaneous and mucocutaneous leishmaniasis. Clin Diagn Lab Immunol 1994; 1: 304-9
24. Melby PC, Neva FA, Sacks DL. Profile of human T cell response to leishmanial antigens: Analysis by immunoblotting. J Clin Invest 1989; 83: 1868-75
25. Mendonca SC, Coutinho SG, Amendoeira RR, et al. Human american cutaneous leishmaniasis (Leishmania b. braziliensis) in Brazil: Lymphoproliferative responses and influence of therapy. Clin Exp Immunol 1986; 64: 269-76
26. Gicheru MM, Olobo JO, Anjili CO, et al. Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect Immun 2001; 69: 245-51
27. Sjolander A, Baldwin TM, Curtis JM, et al. Vaccination with recombinant parasite surface antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. Vaccine 1998; 16: 2077-84
28. Prina E, Lang T, Glaichenhaus N, et al. Presentation of the protective parasite antigen LACK by Leishmania-infected macrophages. J Immunol 1996; 156: 4318-27
29. Barral-Netto M, Barral A, Brownell CE, et al. Transforming growth factor-beta in leishmanial infection: A parasite escape mechanism. Science 1992; 257: 545-8
30. Pirmez, C, Yamamura M, Uyemura K, et al. Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest 1993; 91: 1390-5
31. Melby PC, Andrade-Narvaez FJ, Darnell BJ, et al. Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect Immun 1994; 62: 837-42
32. Caceres-Dittmar G, Tapia FJ, Sanchez MA, et al. Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction. Clin Exp Immunol 1993; 91: 500-5
33. Launois P, Swihart KG, Milon G, et al. Early production of IL-4 in susceptible mice infected with Leishmania major rapidly induces IL-12 unresponsiveness. J Immunol 1997; 158: 3317-24
34. Gurunathan S, Sacks DL, Brown DR, et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 1997; 186: 1137-47
35. Moll H. Scollay R, Mitchell GF. Resistance to cutaneous leishmaniasis in nude mice injected with L3T4+ T cells but not with Ly-2+ T cells. Immunol Cell Biol 1988; 66: 57-63
36. Muller I, Pedrazzini T, Kropf P, et al. Establishment of resistance to Leishmania major infection in susceptible BALB/c mice requires parasite-specific CD8+ T cells. Int Immunol 1991; 3: 587-97
37. Muller I, Kropf P, Etges RJ, et al. Gamma interferon response in secondary Leishmania major infection: Role of CD8+ T cells. Infect Immun 1993; 61: 3730-8
38. Gurunathan S, Stobie L, Prussin C, et al. Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: A potential immunoregulatory role for CD8+ T cells. J Immunol 2000; 165: 915-24
39. Fruth U, Solioz N, Louis JA. Leishmania major interferes with antigen presentation by infected macrophages. J Immunol 1993; 150: 1857-64
40. Nandan D, Reiner NE. Attenuation of gamma interferon-induced tyrosine phosphorylation in mononuclear phagocytes infected with Leishmania donovani: Selective inhibition of signaling through Janus kinases and Stat1. Infect Immun 1995; 63: 4495-500
41. Reiner NE. Ng W, Ma T, et al. Kinetics of gamma interferon binding and induction of major histocompatibility complex class II mRNA in Leishmania-infected macrophages. Proc Natl Acad Sci U S A 1988; 85: 4330-4
42. Reiner NE, Ng W, Wilson CB, et al. Modulation of in vitro monocyte cytokine responses to Leishmania donovani: Interferon-gamma prevents parasite-induced inhibition of interleukin 1 production and primes monocytes to respond to Leishmania by producing both tumor necrosis factor-alpha and interleukin 1. J Clin Invest 1990; 85: 1914-24
43. Reiner NE, Malemud CJ. Arachidonic acid metabolism by murine peritoneal macrophages infected with Leishmania donovani: In vitro evidence for parasite-induced alterations in cyclooxygenase and lipoxygenase pathways. J Immunol 1985; 134: 556-63
44. Reiner NE. Parasite accessory cell interactions in murine leishmaniasis: I, evasion and stimulus-dependent suppression of the macrophage interleukin 1 response by Leishmania donovani. J Immunol 1987; 138: 1919-25
45. Reiner NE, Ng W, McMaster WR. Parasite-accessory cell interactions in murine leishmaniasis: II, Leishmania donovani suppresses macrophage expression of class I and class II major histocompatibility complex gene products. J Immunol 1987; 138: 1926-32
46. Olivier M, Brownsey RW, Reiner NE. Defective stimulus-response coupling in human monocytes infected with Leishmania donovani is associated with altered activation and translocation of protein kinase C. Proc Natl Acad Sci U S A 1992; 89: 7481-5
47. Terkeltaub R, Firestein GS, Kornbluth RS, et al. The effects of gamma-interferon on human peripheral blood monocyte/macrophage-mediated bone particle degradation. Bone Miner 1990; 8: 131-43
48. Firestein GS, Zvaifler NJ. Down regulation of human monocyte differentiation antigens by interferon gamma. Cell Immunol 1987; 104: 343-54
49. Ahmed R, Gray D. Immunological memory and protective immunity: Understanding their relation. Science 1996; 272: 54-60
50. Kenney RT, Sacks DL, Sypek JP, et al. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol 1999; 163: 4481-8
51. Stobie L, Gurunathan S, Prussin C, et al. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. Proc Natl Acad Sci U S A 2000; 97: 8427-32
52. Kamhawi S, Belkaid Y, Modi G, et al. Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies. Science 2000; 290: 1351-4
53. Belkaid Y, Valenzuela JG, Kamhawi S, et al. Delayed-type hypersensitivity to Phlebotomus papatasi sand fly bite: An adaptive response induced by the fly? Proc Natl Acad Sci U S A 2000; 97: 6704-9
54. Belkaid Y, Kamhawi S, Modi G, et al. Development of a natural model of cutaneous leishmaniasis: Powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J Exp Med 1998; 188: 1941-53
55. Titus RG, Ribeiro JM. Salivary gland lysates from the sand fly Lutzomyia longipalpis enhance Leishmania infectivity. Science 1988; 239: 1306-8
56. Valenzuela JG, Belkaid Y, Garfield MK, et al. Toward a defined anti-Leishmania vaccine targeting vector antigens: Characterization of a protective salivary protein. J Exp Med 2001; 194: 331-42
57. Manson-Bahr PEC. Active immunization in leishmaniasis. In: Garnham PCC, Pierce AE, Roitt J, editors. Immunity to Protozoa. Oxford: Blackwell Scientific Publications, 1963: 246-52
58. Nicolle MMC, Manceaux L. Recherches sur le bouton d'Orient. Annales de l'Institut Pasteur 1910; 24: 673-720
59. Melby PC. Experimental leishmaniasis in humans: Review. Rev Infect Dis 1991; 13: 1009-17
60. Naggan L, Gunders AE, Michaeli D. Follow-up study of a vaccination programme against cutaneous leishmaniasis: II, vaccination with a recently isolated strain of L. tropica from Jericho. Trans R Soc Trop Med Hyg 1972; 66: 239-43
61. Hoare CA. Cutaneous leishmaniasis: Critical review of recent Russian work. Trop Dis Bull 1944; 41: 331-45
62. Katzenellenbogen I. Vaccination against oriental sore: Report of results of five hundred and fifty-five inoculations. Arch Dermatol Syph 1944; 50: 239-42
63. Modabber F. Experiences with vaccines against cutaneous leishmaniasis: Of men and mice. Parasitology 1989; 98 Suppl.: S49-60
64. Modabber F. Vaccines against leishmaniasis. Ann Trop Med Parasitol 1995; 89 Suppl. 1: 83-8
65. Handman E, Hocking RE, Mitchell GF, et al. Isolation and characterization of infective and non-infective clones of Leishmania tropica. Mol Biochem Parasitol 1983; 7: 111-26
66. Mitchell GF, Handman E, Spithill TW. Vaccination against cutaneous leishmaniasis in mice using nonpathogenic cloned promastigotes of Leishmania major and importance of route of injection. Aust J Exp Biol Med Sci 1984; 62: 145-53
67. Howard JG, Nicklin S, Hale C, et al. Prophylactic immunization against experimental leishmaniasis: I, protection induced in mice genetically vulnerable to fatal Leishmania tropica infection. J Immunol 1982; 129: 2206-12
68. Liew FY, Howard JG, Hale C. Prophylactic immunization against experimental leishmaniasis: III, protection against fatal Leishmania tropica infection induced by irradiated promastigotes involves Lyt-1+2- T cells that do not mediate cutaneous DTH. J Immunol 1984; 132: 456-61
69. Howard JG, Liew FY, Hale C, et al. Prophylactic immunization against experimental leishmaniasis: II, further characterization of the protective immunity against fatal Leishmania tropica infection induced by irradiated promastigotes. J Immunol 1984; 132: 450-5
70. Liew FY, Hale C, Howard JG. Prophylactic immunization against experimental leishmaniasis: IV, subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection. J Immunol 1985; 135: 2095-101
71. Rivier D, Shah R, Bovay P, et al. Vaccine development against cutaneous leishmaniasis: Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge. Parasite Immunol 1993; 15: 75-84
72. Aebischer T, Morris L, Handman E. Intravenous injection of irradiated Leishmania major into susceptible BALB/c mice: Immunization or protective tolerance. Int Immunol 1994; 6: 1535-43
73. Veras P, Brodskyn C, Balestieri F, et al. A dhfr-ts-Leishmania major knockout mutant cross-protects against Leishmania amazonensis. Mem Inst Oswaldo Cruz 1999; 94: 491-6
74. Titus RG, Gueiros-Filho FJ, de Freitas LA, et al. Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci U S A 1995; 92: 10267-71
75. Alexander J, Coombs GH, Mottram JC. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J Immunol 1998; 161: 6794-801
76. Pessoa SB. Segunda nota sobre a vacinacao preventiva na leishmaniose tegumentar americana com leptomonas mortas. Rev Paul Med 1941; 19: 1-9
77. Pessoa SB. Profilaxia da leishmaniose tegumentar no Estado de Sao Paulo. Folha Med 1941; 22: 157-61
78. Mayrink W, da Costa CA, Magalhaes PA, et al. A field trial of a vaccine against American dermal leishmaniasis. Trans R Soc Trop Med Hyg 1979; 73: 385-7
79. Mayrink W, Williams P, da Costa CA, et al. An experimental vaccine against American dermal leishmaniasis: Experience in the State of Espirito Santo, Brazil. Ann Trop Med Parasitol 1985; 79: 259-69
80. Antunes CM, Mayrink W, Magalhaes PA, et al. Controlled field trials of a vaccine against New World cutaneous leishmaniasis. Int J Epidemiol 1986; 15: 572-80
81. Castes M, Blackwell J, Trujillo D, et al. Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG, I: Skin-test reactivity, T-cell proliferation and interferon-gamma production. Vaccine 1994; 12: 1041-51
82. Nascimento E, Mayrink W, da Costa CA, et al. Vaccination of humans against cutaneous leishmaniasis: Cellular and humoral immune responses. Infect Immun 1990; 58: 2198-203
83. Velez ID, Agudelo S, Arbelaez MP, et al. Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: A randomized controlled trial. Trans R Soc Trop Med Hyg 2000; 94: 698-703
84. Armijos RX, Weigel MM, Aviles H, et al. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: Safety, immunogenicity, and efficacy during the first 12 months of follow-up. J Infect Dis 1998; 177: 1352-7
85. Momeni AZ, Jalayer T, Emamjomeh M, et al. A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 1999; 17: 466-72
86. Sharifi I, FeKri AR, Aflatonian MR, et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998; 351: 1540-3
87. Khalil EA, El Hassan AM, Zijlstra EE, et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: A randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000; 356: 1565-9
88. Afonso LC, Scharton TM, Vieira LQ, et al. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994; 263: 235-7
89. Mendez S, Gurunathan S, Kamhawi S, et al. The potency and durability of DNA-and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J Immunol 2001; 166: 5122-8
90. Belkaid Y, Mendez S, Lira R, et al. A natural model of Leishmania major infection reveals a prolonged silent phase of parasite amplification in the skin before the onset of lesion formation and immunity. J Immunol 2000; 165: 969-77
91. Russell DG, Alexander J. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes [published erratum appears in J Immunol 1988 Apr 15; 140 (8): 2858]. J Immunol 1988; 140: 1274-9
92. Rivier D, Bovay P, Shah R, et al. Vaccination against Leishmania major in a CBA mouse model of infection: Role of adjuvants and mechanism of protection. Parasite Immunol 1999; 21: 461-73
93. Handman E, Button LL, McMaster RW. Leishmania major: Production of recombinant gp63, its antigenicity and immunogenicity in mice. Exp Parasitol 1990; 70: 427-35
94. Papadopoulou G, Karagouni E, Dotsika E. ISCOMs vaccine against experimental leishmaniasis. Vaccine 1998; 16: 885-92
95. Gonzalez CR, Noriega FR, Huerta S, et al. Immunogenicity of a salmonella typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana mexicana. Vaccine 1998; 16: 1043-52
96. McSorley SJ, Xu D, Liew FY. Vaccine efficacy of salmonella strains expressing glycoprotein 63 with different promoters. Infect Immun 1997; 65: 171-8
97. Yang DM, Fairweather N, Button LL, et al. Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. J Immunol 1990; 145: 2281-5
98. Xu D, McSorley SJ, Chatfield SN, et al. Protection against Leishmania major infection in genetically susceptible BALB/c mice by gp63 delivered orally in attenuated Salmonella typhimurium (AroA-AroD-). Immunology 1995; 85: 1-7
99. Abdelhak S, Louzir H, Timm J, et al. Recombinant BCG expressing the Leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice. Microbiology 1995; 141: 1585-92
100. Connell ND, Medina-Acosta E, McMaster WR, et al. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63. Proc Natl Acad Sci U S A 1993; 90: 11473-7
101. Olobo JO, Anjili CO, Gicheru MM, et al. Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania major surface glycoprotein' (gp63). Vet Parasitol 1995; 60: 199-212
102. Jardim A, Alexander J, Teh HS, et al. Immunoprotective Leishmania major synthetic T cell epitopes. J Exp Med 1990; 172: 645-8
103. Spitzer N, Jardim A, Lippert D, et al. Long-term protection of mice against Leishmania major with a synthetic peptide vaccine. Vaccine 1999; 17: 1298-300
104. Frankenburg S, Axelrod O, Kutner S, et al. Effective immunization of mice against cutaneous leishmaniasis using an intrinsically adjuvanted synthetic lipopeptide vaccine. Vaccine 1996; 14: 923-9
105. Walker PS, Scharton-Kersten T, Rowton ED, et al. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis. Hum Gene Ther 1998; 9: 1899-907
106. Xu D, Liew FY. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. Immunology 1995; 84: 173-6
107. Champsi J, McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect Immun 1988; 56: 3272-9
108. McMahon-Pratt D, Rodriguez D, Rodriguez JR, et al. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection. Infect Immun 1993; 61: 3351-9
109. Handman E, Symons FM, Baldwin TM, et al. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Infect Immun 1995; 63: 4261-7
110. Sjolander A, Baldwin TM, Curtis JM, et al. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. J Immunol 1998; 160: 3949-57
111. Mougneau E, Altare F, Wakil AE, et al. Expression cloning of a protective Leishmania antigen. Science 1995; 268: 563-6
112. Gurunathan S, Prussin C, Sacks DL, et al. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med 1998; 4: 1409-15
113. Skeiky YA, Kennedy M, Kaufman D, et al. LeIF: A recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J Immunol 1998; 161: 6171-9
114. Soong L, Duboise SM, Kima P, et al. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infect Immun 1995; 63: 3559-66
115. Webb JR, Campos-Neto A, Ovendale PJ, et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 1998; 66: 3279-89
116. Campos-Neto A, Porrozzi R, Greeson K, et al. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun 2001; 69: 4103-8
117. Rafati S, Baba AA, Bakhshayesh M, et al. Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase. Clin Exp Immunol 2000; 120: 134-8
118. Aebischer T, Wolfram M, Patzer SI, et al. Subunit vaccination of mice against new world cutaneous leishmaniasis: Comparison of three proteins expressed in amastigotes and six adjuvants. Infect Immun 2000; 68: 1328-36
119. McConville MJ, Bacic A, Mitchell GF, et al. Lipophosphoglycan of Leishmania major that vaccinates against cutaneous leishmaniasis contains an alkylglycerophosphoinositol lipid anchor. Proc Natl Acad Sci U S A 1987; 84: 8941-5
120. Handman E, Mitchell GF. Immunization with Leishmania receptor for macrophages protects mice against cutaneous leishmaniasis. Proc Natl Acad Sci U S A 1985; 82: 5910-4
121. Mendonca SC, Russell DG, Coutinho SG. Analysis of the human T cell responsiveness to purified antigens of Leishmania: Lipophosphoglycan (LPG) and glycoprotein 63 (gp 63). Clin Exp Immunol 1991; 83: 472-8
122. Jardim A, Tolson DL, Turco SJ, et al. The Leishmania donovani lipophosphoglycan T lymphocyte-reactive component is a tightly associated protein complex. J Immunol 1991; 147: 3538-44
123. Russo DM, Turco SJ, Burns Jr JM, et al. Stimulation of human T lymphocytes by Leishmania lipophosphoglycan-associated proteins. J Immunol 1992; 148: 202-7
124. Jardim A, Funk V, Caprioli RM, et al. Isolation and structural characterization of the Leishmania donovani kinetoplastid membrane protein-11, a major immunoreactive membrane glycoprotein. Biochem J 1995; 305: 307-13
125. Russo DM, Burns Jr JM, Carvalho EM, et al. Human T cell responses to gp63, a surface antigen of Leishmania. J Immunol 1991; 147: 3575-80
126. Julia V, Glaichenhaus N. CD4(+) T cells which react to the Leishmania major LACK antigen rapidly secrete interleukin-4 and are detrimental to the host in resistant B10D2 mice. Infect Immun 1999; 67: 3641-4
127. Julia V, Rassoulzadegan M, Glaichenhaus N. Resistance to Leishmania major induced by tolerance to a single antigen. Science 1996; 274: 421-3
128. Launois P, Maillard I, Pingel S, et al. IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 1997; 6: 541-9
129. Scott P, Caspar P, Sher A. Protection against Leishmania major in BALB/c mice by adoptive transfer of a T cell clone recognizing a low molecular weight antigen released by promastigotes. J Immunol 1990; 144: 1075-9
130. Soussi N, Milon G, Colle JH, et al. Listeria monocytogenes as a short-lived delivery system for the induction of type 1 cell-mediated immunity against the p36/LACK antigen of Leishmania major. Infect Immun 2000; 68: 1498-506
131. Lohman KL, Langer PJ, McMahon-Pratt D. Molecular cloning and characterization of the immunologically protective surface glycoprotein GP46/M-2 of Leishmania amazonensis. Proc Natl Acad Sci U S A 1990; 87: 8393-7
132. McMahon-Pratt D, Traub-Cseko Y, Lohman KL, et al. Loss of the GP46/M-2 surface membrane glycoprotein gene family in the Leishmania braziliensis complex. Mol Biochem Parasitol 1992; 50: 151-60
133. Murray PJ, Spithill TW, Handman E. The PSA-2 glycoprotein complex of Leishmania major is a glycosylphosphatidylinositol-linked promastigote surface antigen. J Immunol 1989; 143: 4221-6
134. Kima PE, Ruddle NH, McMahon-Pratt D. Presentation via the class I pathway by Leishmania amazonensis-infected macrophages of an endogenous leishmanial antigen to CD8+ T cells. J Immunol 1997; 159: 1828-34
135. Silveira FT, Blackwell JM, Ishikawa EA, et al. T cell responses to crude and defined leishmanial antigens in patients from the lower Amazon region of Brazil infected with different species of Leishmania of the subgenera Leishmania and Viannia. Parasite Immunol 1998; 20: 19-26
136. Kemp M, Handman E, Kemp K, et al. The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in humans with naturally acquired immunity to L. major. FEMS Immunol Med Microbiol 1998; 20: 209-18
137. Webb JR, Kaufmann D, Campos-Neto A, et al. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J Immunol 1996; 157: 5034-41
138. Haberer JE, Da-Cruz AM, Soong L, et al. Leishmania pifanoi amastigote antigen P-4: Epitopes involved in T-cell responsiveness in human cutaneous leishmaniasis. Infect Immun 1998; 66: 3100-5
139. Kar S, Soong L, Colmenares M, et al. The immunologically protective P-4 antigen of Leishmania amastigotes: A developmentally regulated single strand-specific nuclease associated with the endoplasmic reticulum. J Biol Chem 2000; 275: 37789-97
140. Skeiky YA, Guderian JA, Benson DR, et al. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J Exp Med 1995; 181: 1527-37
141. Probst P, Skeiky YA, Steeves M, et al. A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor-alpha production and expression of B7-1 in human monocyte-derived antigen-presenting cells. Eur J Immunol 1997; 27: 2634-42
142. Piedrafita D, Xu D, Hunter D, et al. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major. J Immunol 1999; 163: 1467-72
143. Melby PC, Ogden GB, Flores HA, et al. Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library. Infect Immun 2000; 68: 5595-602
144. Scott P, Pearce E, Natovitz P, et al. Vaccination against cutaneous leishmaniasis in a murine model; I, induction of protective immunity with a soluble extract of promastigotes. J Immunol 1987; 139: 221-7
145. Maxwell JR, Weinberg A, Prell RA, et al. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J Immunol 2000; 164: 107-12
146. Klinman DM, Yamshchikov G, Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 1997; 158: 3635-9
147. Krieg AM, Yi AK, Schorr J, et al. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol 1998; 6: 23-7
148. Chu RS, Targoni OS, Krieg AM, et al. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997; 186: 1623-31
149. Jakob T, Walker PS, Krieg AM, et al. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 1998; 161: 3042-9
150. Jakob T, Walker PS, Krieg AM, et al. Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: Implications for the augmentation of Th1 responses. Int Arch Allergy Immunol 1999; 118: 457-61
151. Walker PS, Scharton-Kersten T, Krieg AM, et al. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci U S A 1999; 96: 6970-5
152. Stacey KJ, Blackwell JM. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect Immun 1999; 67: 3719-26